Tags

Type your tag names separated by a space and hit enter

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur Urol. 2012 May; 61(5):994-1003.EU

Abstract

CONTEXT

Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in men affected by one or both conditions, without a significant increase in adverse events. However, the results are inconsistent.

OBJECTIVE

Perform a systematic review and meta-analysis of available prospective and cross-sectional studies on the use of PDE5-Is alone or in combination with α1-adrenergic blockers in patients with LUTS/benign prostatic hyperplasia (BPH).

EVIDENCE ACQUISITION

A systematic search was performed using the Medline, Embase, and Cochrane Library databases through September 2011 including the combination of the following terms: LUTS, BPH, PDE5-Is, sildenafil, tadalafil, vardenafil, udenafil, α-blockers, and α1-adrenergic blocker. The meta-analysis was conducted according to the guidelines for observational studies in epidemiology.

EVIDENCE SYNTHESIS

Of 107 retrieved articles, 12 were included in the present meta-analysis: 7 on PDE5-Is versus placebo, with 3214 men, and 5 on the combination of PDE5-Is with α1-adrenergic blockers versus α1-adrenergic blockers alone, with 216 men. Median follow-up of all RCTs was 12 wk. Combining the results of those trials, the use of PDE5-Is alone was associated with a significant improvement of the International Index of Erectile Function (IIEF) score (+5.5; p<0.0001) and International Prostate Symptom Score (IPSS) (-2.8; p<0.0001) but not the maximum flow rate (Q(max)) (-0.00; p=not significant) at the end of the study as compared with placebo. The association of PDE5-Is and α1-adrenergic blockers improved the IIEF score (+3.6; p<0.0001), IPSS score (-1.8; p = 0.05), and Q(max) (+1.5; p<0.0001) at the end of the study as compared with α-blockers alone.

CONCLUSIONS

The meta-analysis of the available cross-sectional data suggests that PDE5-Is can significantly improve LUTS and erectile function in men with BPH. PDE5-Is seem to be a promising treatment option for patients with LUTS secondary to BPH with or without ED.

Authors+Show Affiliations

Department of Urology, University of Florence, Florence, Italy. maurogacci@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

22405510

Citation

Gacci, Mauro, et al. "A Systematic Review and Meta-analysis On the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination With Α-blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia." European Urology, vol. 61, no. 5, 2012, pp. 994-1003.
Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003.
Gacci, M., Corona, G., Salvi, M., Vignozzi, L., McVary, K. T., Kaplan, S. A., Roehrborn, C. G., Serni, S., Mirone, V., Carini, M., & Maggi, M. (2012). A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology, 61(5), 994-1003. https://doi.org/10.1016/j.eururo.2012.02.033
Gacci M, et al. A Systematic Review and Meta-analysis On the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination With Α-blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol. 2012;61(5):994-1003. PubMed PMID: 22405510.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. AU - Gacci,Mauro, AU - Corona,Giovanni, AU - Salvi,Matteo, AU - Vignozzi,Linda, AU - McVary,Kevin T, AU - Kaplan,Steven A, AU - Roehrborn,Claus G, AU - Serni,Sergio, AU - Mirone,Vincenzo, AU - Carini,Marco, AU - Maggi,Mario, Y1 - 2012/02/25/ PY - 2011/12/30/received PY - 2012/02/14/accepted PY - 2012/3/13/entrez PY - 2012/3/13/pubmed PY - 2012/8/3/medline SP - 994 EP - 1003 JF - European urology JO - Eur Urol VL - 61 IS - 5 N2 - CONTEXT: Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in men affected by one or both conditions, without a significant increase in adverse events. However, the results are inconsistent. OBJECTIVE: Perform a systematic review and meta-analysis of available prospective and cross-sectional studies on the use of PDE5-Is alone or in combination with α1-adrenergic blockers in patients with LUTS/benign prostatic hyperplasia (BPH). EVIDENCE ACQUISITION: A systematic search was performed using the Medline, Embase, and Cochrane Library databases through September 2011 including the combination of the following terms: LUTS, BPH, PDE5-Is, sildenafil, tadalafil, vardenafil, udenafil, α-blockers, and α1-adrenergic blocker. The meta-analysis was conducted according to the guidelines for observational studies in epidemiology. EVIDENCE SYNTHESIS: Of 107 retrieved articles, 12 were included in the present meta-analysis: 7 on PDE5-Is versus placebo, with 3214 men, and 5 on the combination of PDE5-Is with α1-adrenergic blockers versus α1-adrenergic blockers alone, with 216 men. Median follow-up of all RCTs was 12 wk. Combining the results of those trials, the use of PDE5-Is alone was associated with a significant improvement of the International Index of Erectile Function (IIEF) score (+5.5; p<0.0001) and International Prostate Symptom Score (IPSS) (-2.8; p<0.0001) but not the maximum flow rate (Q(max)) (-0.00; p=not significant) at the end of the study as compared with placebo. The association of PDE5-Is and α1-adrenergic blockers improved the IIEF score (+3.6; p<0.0001), IPSS score (-1.8; p = 0.05), and Q(max) (+1.5; p<0.0001) at the end of the study as compared with α-blockers alone. CONCLUSIONS: The meta-analysis of the available cross-sectional data suggests that PDE5-Is can significantly improve LUTS and erectile function in men with BPH. PDE5-Is seem to be a promising treatment option for patients with LUTS secondary to BPH with or without ED. SN - 1873-7560 UR - https://www.unboundmedicine.com/medline/citation/22405510/A_systematic_review_and_meta_analysis_on_the_use_of_phosphodiesterase_5_inhibitors_alone_or_in_combination_with_α_blockers_for_lower_urinary_tract_symptoms_due_to_benign_prostatic_hyperplasia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(12)00227-8 DB - PRIME DP - Unbound Medicine ER -